1. Market Definition & Product Landscape
1.1 What is Squalene?Squalene is a natural triterpenoid hydrocarbon (C₃₀H₅₀). In humans, it is a precursor of cholesterol and a major component of sebum (roughly 12-13%), providing natural hydration and antioxidant protection to the skin .
1.2 Types by SourceThe market is segmented into three distinct supply chains :
| Source Type | Primary Origin | Regulatory Status in EU Cosmetics | 2034 Outlook |
|---|---|---|---|
| Animal-Sourced | Shark Liver Oil | Prohibited (Annex II) | Declining / Niche |
| Plant-Sourced | Olive, Amaranth, Sugarcane | Fully Permitted | Dominant |
| Biosynthetic | Yeast/Microalgae Fermentation | Fully Permitted | Fastest-Growing |
2. Market Dynamics & Forces2.1 Key Drivers
-
The "Clean Beauty" Megatrend: Consumers demand vegan, cruelty-free, and sustainably sourced ingredients. Plant-based squalene fits this narrative perfectly .
-
Vaccine Adjuvant Demand: The COVID-19 pandemic highlighted squalene’s critical role in enhancing immune response (e.g., MF59 and AS03 adjuvants). R&D in flu and malaria vaccines continues to drive pharmaceutical demand .
-
Bioavailability: Squalene is highly absorbable (60-85%) and mimics human sebum, making it superior to many synthetic emollients .
2.2 Industry Challenges
-
Supply Chain Ethics: Approximately 3,000 sharks are killed to produce just 1 ton of shark-derived squalene, raising significant extinction concerns .
-
Price Volatility: Traditional sourcing relies on fishing yields, whereas plant-based sourcing is subject to agricultural commodity prices.
3. Regional Analysis: The European Stronghold
Europe is not just the largest market; it is the strictest regulator. For any supplier looking to establish credibility, understanding the EU framework is mandatory .
3.1 The EU Cosmetics Regulation (EC) No 1223/2009
-
The Ban: Shark-derived squalene is listed under Annex II (Prohibited Substances). This is an absolute barrier to entry for animal-based products in the EU cosmetic sector.
-
The Opportunity: Plant-derived and biosynthetic squalene face no restrictions and are the only compliant options for cosmetic manufacturers operating in the EU .
3.2 Pharmaceutical Standards (Ph. Eur.)References
-
Fortune Business Insights. (2026). *Squalene Market Size, Share & Industry Analysis, 2026-2034* .
-
Dasari, D., et al. (2025). Squalene: A High‐Value Compound for COVID‐19 Vaccine Adjuvants and Beyond. IUBMB Life .
-
Global Industry Analysts. (2025). Squalene Market Report .
-
Shalu, S., et al. (2024). Microbial Squalene: A Sustainable Alternative. Engineering in Life Sciences .
-
ScienceDirect. (2024). Recent advances in squalene: Biological activities, sources, extraction, and delivery systems .
For pharma-grade squalene (vaccines), compliance with the European Pharmacopoeia (Monograph 2805) is required. While shark sources are technically still permitted here, major players like Evonik have launched GMP-grade plant-based squalene, setting a new industry benchmark for safety and purity .
3.3 Country Breakdown (2025 Data)
-
Germany: The largest single market within Europe, driven by high demand for anti-aging cosmetics.https://www.jxserum.com/other-extracts/
-
France: Hub for luxury cosmetics; high demand for "bio" and plant-based certifications.
-
UK: Strong post-Brexit independent regulatory framework that mirrors EU standards on animal cruelty .
4. Competitive Landscape & Trade4.1 Key Global Players
The market features a mix of traditional Japanese suppliers and modern biotech innovators :
-
Traditional: Kishimoto Special Liver Oil (Japan), Maruha Nichiro (Japan).
-
Plant-Based Innovators: Sophim (France), Croda (UK), Amyris (USA - Biosynthetic).
-
Emerging Chinese Suppliers: High-purity plant-sourced manufacturers are gaining significant traction, leveraging cost advantages and scalable production.
4.2 The Price Premium Matrix
-
Commodity (Shark): High volatility, ethical risks, declining acceptance.
-
Value-Added (Plant/Bio): Stable pricing, premium margins (20-30% higher), long-term contracts.
5. Future Outlook & Trends (2026-2034)
1. The Rise of Biosynthetic SqualeneMicrobial fermentation (using engineered yeast or microalgae) is the future. It offers purity independent of weather (agriculture) or fishing quotas, with a lower carbon footprint .
2. Functional Food ExpansionAs studies confirm its cholesterol-lowering and detoxification effects (see ScienceDirect, 2024), squalene is moving beyond capsules into functional beverages and fortified foods.
3. Supply Chain RegionalizationPost-pandemic, buyers are de-risking supply chains. Suppliers offering dual sourcing (e.g., Olive AND Sugarcane) will win over buyers looking for security against crop failures.
6. Strategic Recommendations for Buyers
For procurement managers and R&D directors reading this white paper:
-
Verify Your Source: If you are selling in Europe, ensure your Certificate of Analysis (COA) explicitly states "100% Plant-Derived" . Shark-derived sources are non-compliant.
-
Look for High Purity: For pharmaceutical or high-end cosmetic use, purity requirements exceed 97% . Lower purity requires additional refining.
-
Partner with Integrated Suppliers: Work with suppliers who control the manufacturing process (from crude oil to refined squalene) to ensure traceability.
Conclusion
The global squalene market is at a tipping point. Sustainability is no longer a marketing advantage; it is a regulatory requirement.
For suppliers, the message is clear: Plant-based is the only viable path forward for growth.
For buyers, the time to audit your supply chain is now. Transitioning to plant-derived or biosynthetic squalene mitigates regulatory risk, aligns with ESG goals, and meets the surging consumer demand for ethical beauty and health products.
Media Contact
Company Name: Jiangxi Serum Pharma Industries Co., Ltd.
Email: Send Email
Country: China
Website: https://www.jxserum.com/
